Vyome Holdings (HIND) Restructuring Costs (2024 - 2025)
Vyome Holdings (HIND) posted Restructuring Costs of $711000.0 for Q2 2025, up 77.75% on a QoQ basis from $400000.0 in Q1 2025, and up 233.8% year-over-year from $213000.0 in Q2 2024.
Powered by 
Analysis
Vyome Holdings (HIND) Restructuring Costs (2024 - 2025) Analysis & Trends
Vyome Holdings has reported Restructuring Costs for 2 years, with the latest figure at $711000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Vyome Holdings | 14.46 Mn | 6.57 Mn | 11,658.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 711,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Jun 30, 2024 | 213,000.00 |